

As House Majority Leader, Val Hoyle attempted to sneak legislation through the Oregon State House that would protect her Big Pharma donor and keep insulin prices high. Among Oregon lawmakers, Hoyle was the number one recipient of campaign cash from a pharmaceutical giant who hiked the price of insulin by more than 1,200%.

BACKUP:

According to an analysis from The Lund Report, out of the 90 state lawmakers in Oregon, Val Hoyle was the top recipient of political donations from Eli Lilly between 2011 and 2013:

Editor's Note: The Oregon [House of Representatives](#) consists of 60 elected members while the Oregon [State Senate](#) consists of 30 elected members, meaning that there are 90 elected members in the Oregon State Legislature.

- **Val Hoyle was the top recipient of Eli Lilly money among Oregon lawmakers between 2011 and 2013.** “The Lund Report analyzed campaign finance transactions in 2011, 2012 and 2013. The analysis of the pharmaceutical sector is the second in a series of articles that began with the health insurance industry last week. The next article will focus other top spenders in the healthcare arena. Detailed information about these political donations was obtained from the Secretary of State’s website. Eli Lilly spent \$81,000 and its top legislator was House Majority Leader Val Hoyle, D-Eugene, who received \$9,000. The company also gave \$7,500 to Freeman, \$5,500 to Rep. Jim Weidner, R-McMinnville, and \$3,000 to Senate Minority Leader Ted Ferrioli, R-John Day.” (Christopher David Gray, “Pfizer, Eli Lilly and Genentech Pour Money into State Elections,” [The Lund Report](#), 9/4/13)
- **Between 2011 and 2017, Val Hoyle took \$20,000 from Eli Lilly.** (Oregon Secretary of State, “Campaign Finance Transaction Search,” [Transaction Search Results](#), Accessed: 7/21/22)

Editor's Note: As of August 2022, Val Hoyle’s congressional campaign committee has [not received](#) contributions from Eli Lilly.

Eli Lilly’s Contributions to Val Hoyle					
Tran ID	Tran Date	Filer/Committee	Contributor/Payee	Sub Type	Amount
2643553 -	10/18/17	Friends of Val Hoyle	Eli Lilly and Company	Cash Contribution	\$2,500
1742732 -	6/9/14	Friends of Val Hoyle	Eli Lilly and Company	Cash Contribution	\$5,000
1714452 -	4/28/14	Friends of Val Hoyle	Eli Lilly and Company	Return or Refund of Contribution	\$1,500
1710453 -	4/22/14	Friends of Val Hoyle	Eli Lilly and Company	Cash Contribution	\$1,500
1611721	12/17/13	Friends of Val Hoyle	Eli Lilly and Company	Cash Contribution	\$3,500

1284871	6/27/12	Friends of Val Hoyle	Eli Lilly and Company	Cash Contribution	\$5,000
-					
1124092	12/6/11	Friends of Val Hoyle	Eli Lilly and Company Political Action Committee	Cash Contribution	\$2,500
-					
1077322	9/15/11	Friends of Val Hoyle	Eli Lilly and Company	Cash Contribution	\$1,000
-					
985990	1/8/11	Friends of Val Hoyle	Eli Lilly	Cash Contribution	\$500
TOTAL:					\$20,000

(Oregon Secretary of State, "Campaign Finance Transaction Search," [Transaction Search Results](#), Accessed: 7/21/22)

In February 2014, while serving as Oregon House Majority Leader and chair of the House Rules Committee, Hoyle used her influence to insert an amendment into an unrelated bill for the benefit of her political donor, Eli Lilly, and protect the pharmaceutical giant against competition from generics until 2016:

- **In February 2014, Val Hoyle—then House Majority Leader—“slipped an amendment for pharmaceutical giant Eli Lilly into an unrelated healthcare bill.”** “House Majority Leader Val Hoyle, D-Eugene, has slipped an amendment for pharmaceutical giant Eli Lilly into an unrelated healthcare bill that will protect its patented insulin drug against generic competition while Eli Lilly awaits approval of its own generic. If House Bill 4110 becomes law with the Eli Lilly amendment attached, Type I and Type II diabetics would not have easy access to any generic insulin until a 2013 law restricting biosimilar drugs expires in 2016.” (Christopher David Gray, “Hoyle Pushes Amendment for Eli Lilly, Limiting Generic Insulin for Diabetics,” [The Lund Report](#), 2/21/14)
- **According to *The Lund Report*, Hoyle used her influence as Chair of the House Rules Committee to “insert an amendment into an unrelated bill for the benefit of a political donor, Eli Lilly.”** “House Majority Leader Val Hoyle, D-Eugene, had used her influence as chair of the House Rules Committee to insert an amendment into an unrelated bill for the benefit of a political donor, Eli Lilly. That amendment would have protected the pharmaceutical giant against competition from generic insulin which may receive approval from the U.S. Food & Drug Administration as early as next year.” (Christopher David Gray, “Eli Lilly Amendment Exits Oregon Legislature as it Entered: Quietly,” [The Lund Report](#), 3/7/14)
 - **Hoyle’s amendment would protect Eli Lilly’s patented insulin drug against generic competition while Eli Lilly awaited approval of its own generic.** “House Majority Leader Val Hoyle, D-Eugene, has slipped an amendment for pharmaceutical giant Eli Lilly into an unrelated healthcare bill that will protect its patented insulin drug against generic competition while Eli Lilly awaits approval of its own generic. If House Bill 4110 becomes law with the Eli Lilly amendment attached, Type I and Type II diabetics would not have easy access to any generic insulin until a 2013 law restricting biosimilar drugs expires in 2016.” (Christopher David Gray, “Hoyle Pushes Amendment for Eli Lilly, Limiting Generic Insulin for Diabetics,” [The Lund Report](#), 2/21/14)

- **If Hoyle’s amendment became law, Type I and Type II diabetics would not have easy access to any generic insulin until 2016.** “If House Bill 4110 becomes law with the Eli Lilly amendment attached, Type I and Type II diabetics would not have easy access to any generic insulin until a 2013 law restricting biosimilar drugs expires in 2016.” (Christopher David Gray, “Hoyle Pushes Amendment for Eli Lilly, Limiting Generic Insulin for Diabetics,” [The Lund Report](#), 2/21/14)
- **Hoyle’s amendment slipped out of the Capitol in the same way it appeared – “quietly, in an irregular committee at an odd hour.”** “The amendment that would restrict pharmacists from dispensing generic insulin slipped out of the Capitol in the same way it appeared – quietly, in an irregular committee at an odd hour. The Joint Capital Construction budget subcommittee voted to delete the amendment from House Bill 4110 at its 7:45 p.m. meeting on Wednesday. The full Ways & Means Committee approved HB 4110 without the amendment at its 8 p.m. meeting on Thursday.” (Christopher David Gray, “Eli Lilly Amendment Exits Oregon Legislature as it Entered: Quietly,” [The Lund Report](#), 3/7/14)

According to a report from the U.S. House Oversight Committee, Eli Lilly has increased the price of Humalog—one of its top insulin products—by more than 1,200% since the product was launched:

- **According to a report from the U.S. House Oversight Committee, Eli Lilly increased the price of Humalog— one of its top insulin product—by 1,219% per vial since it launched.** “Drugmakers have targeted the U.S. market to earn outsized profits from old medicines, according to a report released on Friday by the House Oversight Committee that highlighted Eli Lilly and Co (LLY.N), Novo Nordisk (NOVOB.CO) and Sanofi (SASY.PA), which dominate the market for insulin... Among big-selling insulin products, Eli Lilly raised the price of its Humalog 1,219% per vial since it launched, Novo Nordisk raised the price of NovoLog 627% since launch and Sanofi has raised the price of Lantus 715%, the report found.” (Diane Bartz, “Drugmakers aim big price hikes at U.S. patients, congressional report finds,” [Reuters](#), 12/10/21)
- **The House Oversight Committee’s report revealed that between 1996 to 2017, Eli Lilly increased the price of Humalog a total of 34 times.** “Since 1996, Eli Lilly has been the sole U.S. manufacturer of Humalog, a rapid-acting form of insulin used to control high blood sugar in adults and children with diabetes. Eli Lilly has significantly raised the price of Humalog since it was approved in 1996. From 1996 to 2017, Eli Lilly raised the price of its 10 mL vial of Humalog subcutaneous solution a total of 34 times for a cumulative price increase of more than 1,200%. In 12 of those years, Eli Lilly increased Humalog’s price at least two times. By 2017, a single 10 mL vial of Humalog subcutaneous solution was priced at \$274.70, up from just \$20.82 in 1996.” (U.S. House of Representatives Committee on Oversight and Reform, “Drug Pricing Investigation,” [Majority Staff Report](#), 12/10/21)
 - **VISUAL: Chart showing price increases of various insulin drugs, including Humalog.** (U.S. House of Representatives Committee on Oversight and Reform, “Drug Pricing Investigation,” [Majority Staff Report](#), 12/10/21)

Figure 1: Price Increases and Revenue

Drug	Price Today	No. of Price Increases*	Price Increase Since Launch	2019 U.S. Net Revenue
Copaxone (Teva)	\$85,400/year	25+	825%	\$950 Million
Enbrel (Amgen)	\$72,200/year	25+	486%	\$5.05 Billion
Gleevec (Novartis)	\$123,000/year	20+	395%	\$330 Million
H.P. Acthar (Mallinckrodt)	\$39,864/vial	5	> 100,000%	\$953 Million
Humalog (Eli Lilly)	\$274.70/vial	30+	1219%	\$1.67 Billion
Humira (AbbVie)	\$71,600/year	25+	471%	\$14.9 Billion
Imbruvica (AbbVie)	\$181,500–\$242,000/year	5+	82%	\$3.83 Billion
Lantus (Sanofi)	\$283.56/vial	20+	715%	\$1.14 Billion
Lyrica (Pfizer)	\$1,200/year	20+	420%	\$2.01 Billion
NovoLog (Novo Nordisk)	\$289.36/vial	25+	627%	\$1.18 Billion
Revlimid (Celgene/BMS)	\$192,000/year	20+	255%	\$6.27 Billion
Sensipar (Amgen)	\$9,800/year	20+	232%	\$252 Million


* Number of price increases since launch or acquisition

(U.S. House of Representatives Committee on Oversight and Reform, “Drug Pricing Investigation,” [Majority Staff Report](#), 12/10/21)

- VISUAL: Graph showing the increase in price for a 10 ML vial of Humalog between 1996 to 2021. (U.S. House of Representatives Committee on Oversight and Reform, “Drug Pricing Investigation,” [Majority Staff Report](#), 12/10/21)

Figure 9 shows the increase in price for the 10 mL vial of Humalog subcutaneous solution and the Humalog Kwikpen from 1996 to the present.⁹²

Figure 9: Humalog Price Increases



(U.S. House of Representatives Committee on Oversight and Reform, “Drug Pricing Investigation,” [Majority Staff Report](#), 12/10/21)

- As Eli Lilly raised the price of Humalog from approximately \$40 in 2002 to approximately \$275 by 2018, annual U.S. net revenue for the drug increased more than three-fold—from \$528 million in 2002 to \$1.79 billion in 2018. “As Eli Lilly raised the price of Humalog, from \$39.75 in 2002 to \$274.70 by 2018, annual U.S. net revenue for the drug increased more than three-fold—from \$528 million in 2002 to \$1.79 billion in

2018. Humalog began facing biosimilar competition in January 2018, and Eli Lilly introduced its own authorized generic in March 2019.” (U.S. House of Representatives Committee on Oversight and Reform, “Drug Pricing Investigation,” [Majority Staff Report](#), 12/10/21)

- **The net price of Eli Lilly’s Humalog insulin peaked in 2013, when list price hit \$164.69 and net price reached \$80.46.** “According to Eli Lilly documents, Humalog’s net price peaked in 2013. In 2001, Humalog’s list price was \$41.84, and its net price was \$36.59. In 2013, when the list price hit \$164.69, Humalog’s net price reached \$80.46. Even as the net price of Humalog decreased slightly over the next three years, the drug’s 2016 net price of \$70.30 was still nearly double the net price at launch.” (U.S. House of Representatives Committee on Oversight and Reform, “Drug Pricing Investigation,” [Majority Staff Report](#), 12/10/21)

Editor’s Note: Eli Lilly’s Humalog insulin hit peak net price in 2013 – around the same time that Val Hoyle was the [top recipient](#) (among Oregon lawmakers) of political contributions from the company.